TWD 70.8
(0.28%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 74.32 Million TWD | 11.62% |
2022 | 66.58 Million TWD | 208.57% |
2021 | 21.58 Million TWD | -36.59% |
2020 | 34.03 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 71.29 Million TWD | -2.09% |
2024 Q1 | 72.81 Million TWD | -2.03% |
2023 Q2 | 77.32 Million TWD | 0.0% |
2023 FY | 74.32 Million TWD | 11.62% |
2023 Q4 | 74.32 Million TWD | 0.0% |
2023 Q3 | - TWD | -100.0% |
2023 Q1 | - TWD | -100.0% |
2022 FY | 66.58 Million TWD | 208.57% |
2022 Q4 | 66.58 Million TWD | 0.0% |
2021 FY | 21.58 Million TWD | -36.59% |
2020 FY | 34.03 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Apex Biotechnology Corp. | 180.83 Million TWD | 58.896% |
Sinphar Pharmaceutical Co.,Ltd. | 1.94 Billion TWD | 96.179% |
Panion & Bf Biotech Inc. | 727.83 Million TWD | 89.788% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.2 Billion TWD | 93.853% |
GenMont Biotech Incorporation | 58.3 Million TWD | -27.477% |
Abnova (Taiwan) Corporation | 7.7 Million TWD | -864.547% |
Adimmune Corporation | 3.14 Billion TWD | 97.635% |
Tanvex BioPharma, Inc. | 1.73 Billion TWD | 95.708% |
Polaris Group | 1.19 Billion TWD | 93.796% |
Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
PELL Bio-Med Technology Co. Ltd. | 172.55 Million TWD | 56.926% |